U.S. markets open in 4 hours 25 minutes
  • S&P Futures

    4,173.00
    -3.25 (-0.08%)
     
  • Dow Futures

    34,028.00
    -53.00 (-0.16%)
     
  • Nasdaq Futures

    14,034.25
    +4.75 (+0.03%)
     
  • Russell 2000 Futures

    2,250.60
    -8.40 (-0.37%)
     
  • Crude Oil

    63.13
    0.00 (0.00%)
     
  • Gold

    1,788.10
    +7.90 (+0.44%)
     
  • Silver

    26.15
    +0.05 (+0.17%)
     
  • EUR/USD

    1.2031
    +0.0050 (+0.42%)
     
  • 10-Yr Bond

    1.5730
    0.0000 (0.00%)
     
  • Vix

    17.01
    +0.44 (+2.66%)
     
  • GBP/USD

    1.3879
    +0.0040 (+0.29%)
     
  • USD/JPY

    108.0700
    -0.7130 (-0.66%)
     
  • BTC-USD

    56,975.98
    -518.59 (-0.90%)
     
  • CMC Crypto 200

    1,293.99
    -97.72 (-7.02%)
     
  • FTSE 100

    7,037.17
    +17.64 (+0.25%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

AbbVie To Beef Up Neurology Pipeline With Option To Add Parkinson's Candidate

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • AbbVie Inc (NYSE: ABBV) has landed an option to buy Mitokinin upon completing IND-enabling studies on the latter's lead PINK1 compound for Parkinson's disease.

  • Mitokinin's novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to Parkinson's disease.

  • Mitokinin is based on technology discovered by Nicholas Hertz, Ph.D., and Kevan Shokat, Ph.D., at the University of California, San Francisco.

  • Now, AbbVie has signed up to help Mitokinin get to the next stage in its evolution. In return for the option to buy Mitokinin, AbbVie is making an upfront payment.

  • Price Action: ABBV shares are up 0.1% at $108.5 in market trading hours on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.